Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
F

Prezzo Ford Motor

F
$12,40
-$0,09(-0,72%)

*Data last updated: 2026-04-28 22:09 (UTC+8)

As of 2026-04-28 22:09, Ford Motor (F) is priced at $12,40, with a total market cap of $48,96B, a P/E ratio of -6,38, and a dividend yield of 4,80%. Today, the stock price fluctuated between $12,25 and $12,47. The current price is 1,22% above the day's low and 0,56% below the day's high, with a trading volume of 30,56M. Over the past 52 weeks, F has traded between $9,88 to $14,79, and the current price is -16,15% away from the 52-week high.

F Key Stats

Yesterday's Close$12,38
Market Cap$48,96B
Volume30,56M
P/E Ratio-6,38
Dividend Yield (TTM)4,80%
Dividend Amount$0,15
Diluted EPS (TTM)2,06
Net Income (FY)-$8,18B
Revenue (FY)$187,26B
Earnings Date2026-04-29
EPS Estimate0,20
Revenue Estimate$42,66B
Shares Outstanding3,95B
Beta (1Y)1.71
Ex-Dividend Date2026-02-13
Dividend Payment Date2026-03-02

About F

Ford Motor Company develops, delivers, and services a range of Ford trucks, commercial cars and vans, sport utility vehicles, and Lincoln luxury vehicles worldwide. It operates through Ford Blue, Ford Model e, and Ford Pro; Ford Next; and Ford Credit segments. The company sells Ford and Lincoln vehicles, service parts, and accessories through distributors and dealers, as well as through dealerships to commercial fleet customers, daily rental car companies, and governments. It also engages in vehicle-related financing and leasing activities to and through automotive dealers. In addition, the company provides retail installment sale contracts for new and used vehicles; and direct financing leases for new vehicles to retail and commercial customers, such as leasing companies, government entities, daily rental companies, and fleet customers. Further, it offers wholesale loans to dealers to finance the purchase of vehicle inventory; and loans to dealers to finance working capital and enhance dealership facilities, purchase dealership real estate, and other dealer vehicle programs. The company was incorporated in 1903 and is based in Dearborn, Michigan.
SectorConsumer Cyclical
IndustryAuto - Manufacturers
CEOJames Duncan Farley Jr.
HeadquartersDearborn,MI,US
Official Websitehttp://www.corporate.ford.com
Employees (FY)169,00K
Average Revenue (1Y)$1,10M
Net Income per Employee-$48,41K

Ford Motor (F) FAQ

What's the stock price of Ford Motor (F) today?

x
Ford Motor (F) is currently trading at $12,40, with a 24h change of -0,72%. The 52-week trading range is $9,88–$14,79.

What are the 52-week high and low prices for Ford Motor (F)?

x

What is the price-to-earnings (P/E) ratio of Ford Motor (F)? What does it indicate?

x

What is the market cap of Ford Motor (F)?

x

What is the most recent quarterly earnings per share (EPS) for Ford Motor (F)?

x

Should you buy or sell Ford Motor (F) now?

x

What factors can affect the stock price of Ford Motor (F)?

x

How to buy Ford Motor (F) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

F
CFD
Fai trading

Ford Motor (F) Latest News

2026-04-27 12:31

Russian Troops Allegedly Turn to Cannibalism as Logistics Collapse in Ukraine

Gate News message, April 27 — Ukrainian military intelligence claims Russian soldiers on the frontline have allegedly resorted to cannibalism due to starvation and collapsing supply lines during the brutal winter campaign in Ukraine. Intelligence chiefs in Kyiv assert they have documented at least five separate cases of cannibalism within Russian ranks, backed by intercepted audio files, photos, and Telegram messages obtained by Ukrainian cyber experts. One documented case involves a soldier nicknamed "Khromoy" (Russian for "Limpy"), allegedly caught in a basement near Myrnohrad in the Donetsk region after killing two fellow soldiers and attempting to consume one of them. In a leaked Telegram exchange, an officer reported: "In short, one ally killed two others and he tried—he cut off a leg and was already trying to eat one of them." Another intercepted message from a commander stated: "Ours will also soon start eating each other. All the guys are skinny. Everyone is on starvation rations." Specialist AI detection software analyzed images from the scene and concluded they had not been doctored; a conflict surgeon examining the photos noted that wounds were consistent with sharp knife marks rather than battlefield shrapnel. The Kremlin's Embassy in London dismissed the claims as "propaganda" and "fabrications." Western analysts attribute the underlying cause to a total failure of Russian logistics. Bradley Martin, a former U.S. naval captain and researcher at the Rand Corporation, noted that troop welfare is simply "not a major priority" for the Kremlin. Military analyst Vikram Mittal added that the particularly harsh winter and Ukraine's relentless drone strikes on resupply trucks have left many Russian units completely cut off from food supplies.

2026-04-25 08:17

Turkey May Join Hormuz Strait Demining Operation After U.S.-Iran Peace Deal, Foreign Minister Says

Gate News message, April 25 — Turkish Foreign Minister Hakan Fidan said Turkey could consider participating in demining operations in the Strait of Hormuz if the United States and Iran reach a peace agreement. A technical team would conduct the demining work in the strait following any agreement, Fidan stated. Turkey views such operations as a humanitarian responsibility and maintains a positive stance on participation in principle. Turkey would reassess its position if the technical coalition becomes a party to future conflict. Fidan also expressed confidence that issues related to Iran's nuclear program can be resolved in upcoming talks to be held in Pakistan.

2026-04-25 00:45

China's NDRC Directs AI Firms Including Moonshot and StepFun to Reject U.S. Capital Without Approval

Gate News message, April 25 — China's National Development and Reform Commission (NDRC) has directed multiple AI companies to reject U.S. capital in recent weeks unless they obtain explicit government approval, according to Bloomberg citing informed sources. Moonshot AI and StepFun, both preparing for IPO listings, have received the NDRC's guidance. ByteDance has also been instructed not to introduce new U.S. investors through secondary share transfers or other means without prior authorization. The directive follows Meta's $2 billion acquisition of Chinese AI agent startup Manus. China has previously imposed travel restrictions on Manus co-founders Xiao Hong and Ji Yichao, and is reviewing whether the deal violates technology export controls and foreign investment regulations.

2026-04-24 20:31

Wall Street's High-Risk Trades Lose Investor Conviction; USO Sees Largest Monthly Outflow Since 2009

Gate News message, April 24 — High-conviction trades on Wall Street are rapidly losing favor as risk-conscious investors cash out of crowded positions. USO, the largest U.S. ETF tracking crude oil, is on pace for its steepest monthly outflow since 2009, while SOXX, one of the largest semiconductor funds, is poised for its second-largest weekly withdrawal ever—just one week after recording record inflows. Despite both trades continuing to deliver positive returns, investors are increasingly unwinding their positions, signaling a shift in market sentiment toward risk reduction.

Hot Posts su Ford Motor (F)

WalletManager

WalletManager

9 minuti fa
**Summary** This report provides the real-time exchange rate between the South African Rand (ZAR) and the Brazilian Real (BRL), helping traders quickly grasp market dynamics and identify potential trading opportunities. ## **Definition** The South African Rand (ZAR) and the Brazilian Real (BRL) are major fiat currencies of their respective economies. The exchange rate between them reflects market sentiment toward both currencies and the economic conditions of South Africa and Brazil, serving as an important indicator for emerging market traders and cross-currency investors. ## **Today's Price** - **1 ZAR = 0.301 BRL** - **24h High:** 0.30245 BRL - **24h Low:** 0.30067 BRL ## **Market Analysis** The ZAR/BRL exchange rate is currently trading within a relatively narrow range, with modest volatility observed over the past 24 hours. - **Technical levels:** Key support at 0.30067 BRL, resistance at 0.30245 BRL - **Trading opportunities:** Monitor price action within the established 24-hour range for potential entry and exit points ## **Conclusion** Continue to monitor the ZAR/BRL pair closely for emerging trading opportunities. Traders should remain attentive to any developments that may impact either currency's performance in the broader emerging market context.
0
0
0
0
BraveNewCoin

BraveNewCoin

51 minuti fa
On April 16, Health and Human Services Secretary Robert F. Kennedy Jr. confirmed the FDA will convene its Pharmacy Compounding Advisory Committee in July to reconsider a slate of peptides the Biden-era FDA designated as “Category 2” — bulk drug substances flagged for “significant safety risks.” A second panel is scheduled for February 2027. Twelve peptides are on the docket: BPC-157, Thymosin beta-4 fragment (LKKTETQ), Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, Ibutamoren Mesylate, Melanotan II, KPV, Semax, and Cathelicidin LL-37. ![The peptide market is on track to add roughly $130 billion in value over the next decade with or without Kennedy's Category 2 reversal. The reversal just determines who captures it — regulated U.S. compounders and telehealth platforms, or offshore vendors with TikTok storefronts.](https://bravenewcoin.com/wp-content/uploads/2026/04/Screenshot-2026-04-29-at-9.03.34-AM-1024x631.png) *Today, we took long-overdue action to restore science, accountability, and the rule of law, said Kennedy, source: X* To anyone who watched crypto’s regulatory cycle, the political economy is recognizable. A previous administration treated the category as inherently suspect and pushed users offshore. A new administration argues the restriction created the very problem it was meant to solve and is reopening the regulated channel. “We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve,” Kennedy said in his April statement. Critics aren’t convinced. “Everybody knows the outcome that the secretary wants,” Peter Lurie, a former FDA associate commissioner, told NBC News, arguing the review is unlikely to produce honest scrutiny. Bitcoin maximalists made the same argument about the SEC’s 2024 about-face, and the price action didn’t care. ## The setup, in markets terms Peptide therapeutics — short chains of amino acids that act as biological signaling molecules — are not a fringe category. The global market was valued at roughly $141 billion in 2025 and is projected to reach about $164 billion this year, on track to nearly double to $295 billion by 2033. Insulin is a peptide. So is semaglutide. So is tirzepatide. The branded, FDA-approved end of the market is one of pharma’s largest and fastest-growing categories. The contested end — the twelve compounds on Kennedy’s list — sits in the same regulatory shadow that offshore crypto exchanges occupied circa 2022. Compounding pharmacies were preparing peptides under the FDA’s Section 503A framework until the 2023 Category 2 reclassification effectively shut them out. Demand didn’t disappear; it routed offshore. TikTok and Telegram vendors now sell vials labeled “research use only” for as little as $5, most of them sourced from Chinese laboratories outside U.S. drug standards. The parallel to unregulated offshore exchanges, sanctions-evading mixers, and crypto’s grey supply chain isn’t subtle. The regulated US channel got squeezed; demand migrated to jurisdictions where quality is whatever the seller says it is. The retail demand signal is also familiar. Google search interest in “peptides” rose 80% in the United States between April 2025 and April 2026, according to trend data compiled by Open Loop Health, with queries for “cost of peptide therapy” up 300%. Joe Rogan and Andrew Huberman are doing for BPC-157 what Michael Saylor and Anthony Pompliano did for Bitcoin: pulling a category into mainstream consciousness through high-trust audiences well before the regulatory framework catches up. ## The spot-ETF moment What makes this more than a wellness trend is what’s happening at the institutional end of the same molecule class. Eli Lilly’s investigational triple-receptor agonist retatrutide — itself a synthetic peptide — has produced the most dramatic obesity trial results on record. In December, Lilly’s TRIUMPH-4 study reported average weight loss of up to 23.7% (about 60 pounds) at the highest dose over 68 weeks, alongside significant reductions in osteoarthritis knee pain. A March 2026 Type 2 diabetes readout showed up to 17% weight loss and 2-point A1c reductions at 40 weeks. Seven additional Phase 3 readouts are expected through year-end, with FDA filing anticipated Q4 2026 or Q1 2027. For peptides as an asset class, retatrutide is the equivalent of BlackRock filing for IBIT. Once a major institution proves the thesis can clear the highest bar — a Phase 3 trial, a spot ETF — the category gets re-rated. Capital that previously stayed away on credibility grounds starts looking for adjacent exposure. The wider peptide thesis no longer rests on Rogan-podcast anecdotes; it rests on data from a $700 billion drugmaker. ## The investable surface The publicly tradable proxies are already moving. Hims & Hers shares jumped on Kennedy’s April announcement on the view that compounded peptides could become the next growth lane after GLP-1s, with Leerink calling it a clearer regulatory path to scale. The setup mirrors the Coinbase trade: a public-equity vehicle whose valuation tracks the regulatory tailwind for the underlying category. The infrastructure layer is moving harder. Lilly is committing more than $6 billion to a new active pharmaceutical ingredient plant in Huntsville, Alabama, with peptide manufacturing as a core mandate. CordenPharma, Cambrex, and Lupin Manufacturing Solutions have all expanded peptide capacity in the past 12 months. In capital-allocation terms, this is the Strategy / Marathon move — operators making multi-billion-dollar bets on a category continuing to compound for a decade. Branded peptide therapeutics already account for more than 60% of the segment’s revenue, with North America holding roughly 38% of the global market. ## Where crypto and peptides actually overlap There is also a direct on-chain expression of the peptide thesis. VitaDAO, the decentralized longevity-research collective, has spent the past several years funding early-stage aging and longevity science through community governance, with its VITA token coordinating treasury decisions. PoSciDonDAO, profiled previously by BNC, runs a similar model for personalized medicine research funding. The Venn diagram between crypto-native investors and longevity bettors — Bryan Johnson’s audience, the Rogan-Huberman demographic, the Balaji Srinivasan thesis — overlaps almost entirely. DeSci tokens are, in a real sense, the only liquid way to express a longevity-science thesis at the protocol level. As the peptide category re-rates, that adjacent on-chain market is one of the more interesting beta plays on the same macro story. ## The top six on the slate Of the twelve peptides under FDA review, six dominate the clinical and consumer conversation: **BPC-157** — Synthetic fragment of a gastric-juice protein, used for tendon, ligament, and gut healing. Animal data extensive, human trials sparse. Almost certainly the headline name at the July panel. **GHK-Cu (copper peptide)** — Naturally occurring tripeptide used both in skincare and as an injectable for wound healing and skin remodeling. Among the better-evidenced peptides on the list. **Epitalon** — Soviet-developed four–amino-acid peptide marketed as a telomerase activator. Thin human data, mostly from a single research group. Flagship of the longevity-clinic circuit. **MOTS-c** — Mitochondrial-derived peptide with credible academic interest in metabolic regulation and exercise mimicry. Mechanistic story is strong; Phase 3 data does not yet exist. **Thymosin beta-4 fragment (LKKTETQ)** — Active fragment of TB-500, used for soft-tissue repair. Parent compound studied in early cardiac and corneal trials. **Ibutamoren (MK-677)** — Technically a non-peptide growth-hormone secretagogue but bundled with the cohort. Clearest pharmacology, most documented side effects: water retention, insulin resistance, increased appetite. The remaining six — DSIP, Dihexa, Melanotan II, KPV, Semax, and Cathelicidin LL-37 — span sleep, cognition, tanning, gut inflammation, and antimicrobial defense. ## Risks that should sound familiar The bear case mirrors crypto’s. The advisory committee is non-binding; rulemaking takes months; the FDA panel currently has multiple vacancies Kennedy can fill before July, raising legitimate process concerns. Most of the twelve peptides have minimal Phase 3 human data and no patent path that would justify building one. Quality control in the existing market is poor — counterparty risk in peptide vials is a meaningful problem the way self-custody-vs-exchange risk is in crypto. And political reversibility cuts both ways: what one administration unlocks, another can re-restrict. What the bull case has going for it is the same thing crypto’s bull case had in early 2024: real capital is being deployed against the thesis at scale. Lilly’s $6 billion plant doesn’t get built on a regulatory whim. The peptide market is on track to add roughly $130 billion in value over the next decade with or without Kennedy’s Category 2 reversal. The reversal just determines who captures it — regulated U.S. compounders and telehealth platforms, or offshore vendors with TikTok storefronts. For investors looking past the next quarter, the trade isn’t whether peptides matter. It’s whether the legitimate end of the supply chain finally gets to participate.
0
0
0
0
AnnaCryptoWriter

AnnaCryptoWriter

1 ore fa
📢 Gate Square | 4/28 Щоденний прогноз Polymarket 🎁 Приєднуйтесь для шансу виграти! 5 щасливих користувачів отримають по $5 у токенах 📝 Як взяти участь: 1️⃣ Голосуйте у прогнозі Polymarket і завершіть торг 2️⃣ Опублікуйте з #DailyPolymarketHotspot та поділіться своїм обґрунтуванням і стратегією 💬 Сьогоднішній прогноз: Яка компанія, на вашу думку, займе #2 місце у глобальному рейтингу за ринковою капіталізацією до кінця квітня? A. Alphabet B. Apple C. NVIDIA D. Microsoft E. Amazon F. Tesla G. Saudi Aramco 👇 Натисніть на картку Polymarket нижче, щоб почати прогнозувати та торгувати Щоб додати картку Polymarket у ваш пост, будь ласка, оновіть додаток до версії 8.17.0 або вище Деталі: https://gate.onelink.me/Hls0/prediction?page=detail&event_ticker=290216&source=cex #GateSquare #Gate $BTC ‌$BTC ‌
BTC-0,77%
BTC-0,77%
0
0
0
0